Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Kory James Wentworth Sells 1,000 Shares of Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Kory James Wentworth sold 1,000 shares of the company’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $19.97, for a total value of $19,970.00. Following the completion of the sale, the chief financial officer now directly owns 73,849 shares of the company’s stock, valued at approximately $1,474,764.53. This trade represents a 1.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Kory James Wentworth also recently made the following trade(s):

• On Monday, December 2nd, Kory James Wentworth sold 5,000 shares of Entrada Therapeutics stock. The shares were sold at an average price of $20.00, for a total value of $100,000.00.
• On Monday, November 11th, Kory James Wentworth sold 8,637 shares of Entrada Therapeutics stock. The stock was sold at an average price of $19.98, for a total transaction of $172,567.26.
• On Monday, September 9th, Kory James Wentworth sold 3,195 shares of Entrada Therapeutics stock. The shares were sold at an average price of $14.97, for a total transaction of $47,829.15.

Entrada Therapeutics Trading Down 0.7 %

NASDAQ TRDA opened at $20.17 on Wednesday. The stock has a market capitalization of $754.76 million, a price-to-earnings ratio of 12.69 and a beta of -0.18. The business’s 50 day moving average is $17.80 and its two-hundred day moving average is $16.38. Entrada Therapeutics, Inc. has a 12-month low of $11.35 and a 12-month high of $20.50.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. US Bancorp DE acquired a new stake in Entrada Therapeutics in the third quarter valued at $42,000. SG Americas Securities LLC purchased a new position in shares of Entrada Therapeutics in the 3rd quarter valued at about $156,000. Acadian Asset Management LLC lifted its stake in shares of Entrada Therapeutics by 135.1% in the second quarter. Acadian Asset Management LLC now owns 13,367 shares of the company’s stock valued at $190,000 after purchasing an additional 7,682 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Entrada Therapeutics by 34.7% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,156 shares of the company’s stock worth $226,000 after buying an additional 3,644 shares in the last quarter. Finally, Public Employees Retirement System of Ohio grew its position in Entrada Therapeutics by 89.1% during the third quarter. Public Employees Retirement System of Ohio now owns 16,259 shares of the company’s stock worth $260,000 after buying an additional 7,659 shares during the period. Institutional investors and hedge funds own 86.39% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on TRDA shares. Oppenheimer raised their price objective on shares of Entrada Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 6th. HC Wainwright upped their price objective on shares of Entrada Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.